Apeiron RIA’s Heron Therapeutics HRTX Stock Holding History

Apeiron RIA’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$114K	Sell	319,123 -51,456	-14%	-$19.5K	0.03%	135
2026 Q2	$158K	Buy	370,579 +64,911	+21%	+$52K	0.04%	162
2026 Q1	$245K	Buy	305,668 +45,700	+18%	+$53K	0.06%	182
2025 Q4	$359K	Buy	259,968 +37,090	+17%	+$45.8K	0.07%	153
2025 Q3	$290K	Sell	222,878 -37,500	-14%	-$59.5K	0.07%	171
2025 Q2	$539K	Sell	260,378 -2,164	-0.8%	-$4.42K	0.14%	118
2025 Q1	$578K	Hold	262,542	–	–	0.17%	110
2024 Q4	$402K	Buy	262,542 +19,000	+8%	+$30.8K	0.11%	138
2024 Q3	$485K	Buy	243,542 +54,907	+29%	+$131K	0.14%	119
2024 Q2	$660K	Buy	188,635 +64,635	+52%	+$199K	0.2%	88
2024 Q1	$343K	Buy	124,000 +41,000	+49%	+$103K	0.1%	153
2023 Q4	$141K	Hold	83,000	–	–	0.04%	198
2023 Q3	$85.5K	Buy	83,000 +31,000	+60%	+$44.1K	0.03%	189
2023 Q2	$60.3K	Buy	52,000 +19,000	+58%	+$33.9K	0.02%	191
2023 Q1	$49.8K	Buy	+33,000	New	+$82.6K	0.02%	193

Other funds holding HRTX

Congress Park Capital Saratoga Springs, New York $381M AUM 20.14% 1-Year Est. Return

Redwood Family Wealth Addison, Texas $113M AUM 24.54% 1-Year Est. Return

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

DDFG Inc Thousand Oaks, California $508M AUM 11.76% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return

Parkway Wealth Management Plano, Texas $869M AUM 25.74% 1-Year Est. Return

Capital Investment Counsel Inc Raleigh, North Carolina $935M AUM 42.84% 1-Year Est. Return

Apeiron RIA's HRTX Position: Q3 2026 in Review

Apeiron RIA reduced its Heron Therapeutics (HRTX) stake by 14% in Q3 2026, selling an estimated $19.5K and leaving 319,123 shares worth $114K. The position accounts for 0.03% of the portfolio, ranked #135.

Apeiron RIA first reported a position in HRTX in Q1 2023 and has held it in 15 quarters since. The position peaked at $660K in Q2 2024. 22 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

Apeiron RIA held 319,123 shares of Heron Therapeutics worth $114K as of Q3 2026.
Apeiron RIA sold 51,456 Heron Therapeutics shares in Q3 2026, an estimated $19.5K.
Heron Therapeutics made up 0.03% of Apeiron RIA's portfolio in Q3 2026, its #135 holding.
Apeiron RIA first reported a position in Heron Therapeutics in Q1 2023 and has held it in 15 quarters since.
Apeiron RIA's Heron Therapeutics position peaked at $660K in Q2 2024.
22 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Apeiron RIA's 13F filing for Q3 2026, filed 8 Oct 2026.